Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of NX210c in healthy elderly volunteers and patients with Alzheimer's disease or Parkinson's disease
NL-OMON53584Completed
- Sponsor
- Axoltis Pharma
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of nx210c in Alzheimer's disease (AD) and Parkinson's disease (PD) (5 arms), sponsored by Axoltis Pharma. Primary endpoint: Safety and tolerability. Started Dec 2022; status: completed.
02
Drugs
nx210c
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON53584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53584.